News for Dyne Therapeutics, Inc. (DYN)

Evercore ISI has started coverage of Dyne Therapeutics (DYN) with an Outperform rating and set a price target of $46. Previously, the firm held reservations abo

H.C. Wainwright has revised its price target for Dyne Therapeutics (DYN), reducing it from $46 to $38 while maintaining a Buy recommendation. This adjustment re

Dyne Therapeutics (DYN) continues to hold a buy rating as Chardan Capital remains optimistic about the company's future prospects. Analyst Keay Nakae has reaffi

Strengths: Innovative FORCE platform and robust pipeline with potential to address unmet needs in neuromuscular diseases.Weaknesses: High R&D expenses and abse

**media[618855]**

Dyne Therapeutics, Inc. (DYN), Thursday announced that the European Commission has granted orphan drug designation for DYNE-251 for the treatment of Duchenne muscular dystrophy or DMD.

Dyne Therapeutics (DYN) has strengthened its leadership team with two strategic appointments. The company has named Vikram Ranade, PhD, as its new Chief Busines

**media[595445,595446,595447,595448]**

WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. ( DYN), a clinical-stage company focused on advancing life-transforming therapeutic

Dyne Therapeutics (DYN) grants inducement equity awards to three new employees. 330,200 non-statutory stock options and 101,900 restricted stock units a

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Friday. Shares of Booz Allen Hamilton Holding Corporation BAH fell sha...

Summary On March 20, 2025, Dyne Therapeutics Inc (DYN), a clinical-stage company dedicated to developing therapeutics for genetically driven neuromuscular disea

- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20,

WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. ( DYN), a clinical-stage company focused on advancing life-transforming therapeutic

**media[572505]**

**media[572477,572478]**

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Dyne Therapeutics (DYN) stock gains premarket momentum as BMO Capital Markets issus a new Outperform rating on the company. Read more here.

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. ( DYN), a clinical-stage company focused on advancing life-transforming therapeutic